Extended Data Fig. 4: Generation of various therapeutic immune cells by MAJESTIC.
a, Quantification of the HER2.CAR T cell viability. b, Quantification of HER2.CAR-positive CD8 T cells. c, Representative flow-cytometry plots of EGFRvIII.CAR-NK92 cells were produced via either the SB system or lentiviral transduction. d, Quantification of (c). e, Quantification of CD19.20.CAR T cells. f, Flow cytometry detection of CD19 and CD20 expression in NALM6-GL cells. g, Cytolysis analysis of NALM6-GL cancer cells that were co-cultured with lenti-CD19.20.CAR and AAV-SB-CD19.20.CAR T cells. Donor 2 and donor VP2 T cells were used in this figure.
